France Influenza Vaccine Market

France Influenza Vaccine Market Insights Forecasts to 2035

• The France Influenza Vaccine Market Size Was Estimated at USD 245.3 Million in 2024
• The France Influenza Vaccine Market Size is Expected to Grow at a CAGR of Around 7.01% from 2025 to 2035
• The France Influenza Vaccine Market Size is Expected to Reach USD 516.6 Million by 2035

 

According to a research report published by Decision Advisor & Consulting, The France Influenza Vaccine Market Size is anticipated to reach USD 516.6 Million by 2035, Growing at a CAGR of 7.01% from 2025 to 2035. The France influenza vaccine market is driven by regular flu seasons, strong government vaccination programs, and high risk among elderly and vulnerable people. Growing awareness of flu prevention and easy access to vaccines also support market growth.

 

Market Overview

The France influenza vaccine market encompasses all of the processes involved with creating, developing, testing, getting approval for, distributing, and administering influenza vaccines to prevent seasonal influenza in France. The market has several different types of influenza vaccines available, including inactivated influenza vaccines, live attenuated vaccines, adjuvanted vaccines, and high-dose vaccines that have been created to protect different demographics of people, including children, adults, elderly people, and high-risk patients with chronic medical conditions.

 

France's demand for the influenza vaccine market is primarily driven by population health and the significant impact of seasonal flu. Influenza affects millions of people in France every year (seasonal influenza affects around 2-3 million people annually), leading to a large number of doctor visits, hospital admissions, and several thousand deaths that are mainly among people aged 65 and above and those with chronic illnesses such as heart, lung, or metabolic diseases. Severe and early flu seasons that put hospitals under pressure thus make vaccination, the most effective preventive measure, get highlighted and, therefore, reinforce the importance of a well-developed influenza vaccine market.

 

The France government is doing everything to meet this need, therefore strongly encouraging influenza vaccination through yearly national campaigns, clear health authority recommendations, and wide reimbursement, including free vaccination for elderly and high-risk groups. Vaccines can be given by doctors, pharmacists, nurses, and midwives. Thus, access is easier. Besides that, disease monitoring and vaccine research are also supported by government agencies through large national health and research budgets. Eventually, raising vaccination rates, using more effective vaccines for seniors, and increasing public awareness will still be the main opportunities for growth in the France influenza vaccine market

.

Report Coverage

This research report categorizes the market for the France influenza vaccine market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France influenza vaccine market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France influenza vaccine market.

 

Driving Factors

The France influenza vaccine market is primarily driven by the high seasonal flu cases, an aging population, and an increased number of people with chronic diseases, who are more susceptible to severe influenza. The government's robust support in terms of national vaccination campaigns, offering of vaccines at no cost, ease of access through pharmacies and healthcare professionals, and the availability of better vaccines are some of the major factors that are contributing to the market growth.

 

Restraining Factors

 

The France influenza vaccine market is restrained by a number of factors. Vaccine hesitancy and low awareness are the main reasons for this limitation.  Also, fear of side effects, doubts about the effectiveness of the vaccine, and misinformation are factors that discourage vaccination. Changes in seasonal demand and lower vaccination among young, healthy people are additional factors that restrain market growth.

 

Market Segmentation

The France influenza vaccine market share is classified into type, indication, age group, route of administration, and distribution channel.

• The inactivated segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France influenza vaccine market is segmented by type into inactivated and live attenuated. Among these, the inactivated segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The inactivated segment is growing because these vaccines are safe, widely recommended, and suitable for elderly people and those with chronic diseases. They are commonly used in national vaccination programs, trusted by doctors, and effective in preventing severe flu, leading to higher adoption and market growth.

 

• The quadrivalent segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France influenza vaccine market is segmented by indication into quadrivalent and trivalent. Among these, the quadrivalent segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The quadrivalent segment is growing because it protects against four influenza virus strains instead of three, offering broader and more effective protection. France health authorities and healthcare providers increasingly prefer quadrivalent vaccines, leading to higher adoption in national vaccination programs and stronger market growth.

 

• The adult segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France influenza vaccine market is segmented by age group into pediatric and adult. Among these, the adult segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The adult segment is growing because adults, especially elderly people and those with long-term health problems, are more likely to get severe flu. They are strongly encouraged to get vaccinated every year, and government support and higher awareness lead to greater vaccine use among adults.

 

• The injection segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France influenza vaccine market is segmented by route of administration into injection and nasal spray. Among these, the injection segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The injection segment is growing because injectable influenza vaccines are widely used, highly trusted, and strongly recommended by health authorities for adults, elderly people, and high-risk patients. They are more effective for most age groups, easy to store and distribute, and commonly used in national vaccination programs, leading to higher adoption.

 

• The hospitals & pharmacies segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France influenza vaccine market is segmented by distribution channel into hospitals & pharmacies and government & institutional supply. Among these, the hospitals & pharmacies segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The hospitals & pharmacies segment is growing because they are the most accessible and commonly used vaccination points for the public. Easy availability of vaccines, pharmacist-led vaccination services, strong patient trust, and support from national vaccination programs drive higher vaccine uptake through hospitals and community pharmacies.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France influenza vaccine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• CSL Seqirus
• Pfizer Inc.
• AstraZeneca
• Moderna, Inc.
• Novavax, Inc.
• Merck & Co., Inc.
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Bharat Biotech International Ltd.
• Hualan Biological Engineering Inc.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments:

• In September 2025, France launched its 2025–2026 winter influenza and COVID-19 vaccination campaign, beginning on 14 October, offering free flu vaccine vouchers for millions of at-risk people and allowing simultaneous flu and COVID shots to help reduce hospital pressure this winter.

 

• In Jul 2025, Sanofi reintroduced its high-dose influenza vaccine Efluelda in France for the 2025–2026 flu season, offering four times more active ingredient and enhanced protection for adults aged 65 and over, following regulatory approval and full reimbursement under national vaccination guidelines.

 

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decision Advisor has segmented the France influenza vaccine market based on the below-mentioned segments:

 

France Influenza Vaccine Market, By Type

• Inactivated
• Live Attenuated

 

France Influenza Vaccine Market, By Indication

• Quadrivalent
• Trivalent

 

France Influenza Vaccine Market, By Age Group

• Pediatric
• Adult

 

France Influenza Vaccine Market, By Route of Administration

• Injection
• Nasal Spray

 

France Influenza Vaccine Market, By Distribution Channel

• Hospitals & Pharmacies
• Government & Institutional supply

 

FAQ’s

1. What is the France influenza vaccine market size in 2024?

The France influenza vaccine market size was estimated at USD 245.3 million in 2024.

 

2. What is the projected market size of the France influenza vaccine market by 2035?

The France influenza vaccine market size is expected to reach USD 516.6 million by 2035.

 

3. What is the CAGR of the France influenza vaccine market?

The France influenza vaccine market size is expected to grow at a CAGR of around 7.01% from 2024 to 2035.

 

4. What are the key growth drivers of the France influenza vaccine market?

The France influenza vaccine market is driven by regular flu seasons, strong government vaccination programs, and high risk among elderly and vulnerable people. Growing awareness of flu prevention and easy access to vaccines also support market growth.

 

5. Which indication segment dominated the market in 2024?

The quadrivalent segment dominated the market in 2024.

 

6. What segments are covered in the France influenza vaccine market report?

The France influenza vaccine market is segmented on the basis of type, indication, age group, route of administration, and distribution channel.

 

7. Who are the key players in the France influenza vaccine market?

Key companies include Sanofi Pasteur, GlaxoSmithKline (GSK), CSL Seqirus, Pfizer Inc., AstraZeneca, Moderna, Inc., Novavax, Inc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Bharat Biotech International Ltd., Hualan Biological Engineering Inc., and others.

 

8. Who are the target audiences for this market report?

           The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).